What is Paradromics?
Paradromics is dedicated to restoring communication and independence for individuals impacted by severe paralysis stemming from conditions such as ALS, stroke, and spinal cord injuries. Their innovative technology, exemplified by the Connexus product, empowers non-verbal individuals to communicate via digital devices. The upcoming Tempo product is set to focus on mental health brain-state monitoring. By utilizing high-resolution brain activity recording and sophisticated AI algorithms, Paradromics translates complex brain data into actionable health insights, addressing a broad spectrum of neurological and mental health challenges. The company's commitment lies in creating scalable and enduring neurotechnology solutions to serve millions with unmet medical needs.
How much funding has Paradromics raised?
Paradromics has raised a total of $61.3M across 5 funding rounds:
Debt
$985K
Angel/Seed
$7M
Debt
$350K
Angel/Seed
$20M
Other Financing Round
$33M
Debt (2015): $985K, investors not publicly disclosed
Angel/Seed (2018): $7M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Angel/Seed (2021): $20M featuring Synergy Ventures, Westcott, Prime Movers Lab, Alpha Edison, IT Farm, Dolby Family Ventures, and Pureland Group
Other Financing Round (2023): $33M backed by Westcott, Dolby Family Ventures, and Green Sands Equity
Key Investors in Paradromics
Synergy Ventures
Synergy Ventures is a VC firm specializing in medical device companies, providing strategic assistance for market entry and corporate relationships, particularly within the Japan market. They have a strong reputation for efficient negotiation and structuring of partnerships.
Westcott
Westcott Investment Group operates as a family investment office, focusing on wealth management and financial services. They are associated with Westcott Industries and are based in Dallas, Texas.
Prime Movers Lab
Prime Movers Lab is a venture capital firm dedicated to funding breakthrough scientific startups that aim to transform industries and improve lives. They support founders with innovative ideas and a growth mentality.
What's next for Paradromics?
The recent major strategic investment signals a pivotal growth phase for Paradromics, likely enabling the company to accelerate product development, expand its research initiatives, and scale its operations. This capital infusion is expected to bolster their efforts in bringing advanced BCI solutions to market, further solidifying their position in the neurotechnology sector. The company's focus on both communication restoration and mental health monitoring suggests a strategic expansion into diverse areas of neurological care, positioning them for significant impact and future advancements in the field.
See full Paradromics company page
